| Autor: |
Kieliszek, Agata M., Mobilio, Daniel, Bassey-Archibong, Blessing I., Johnson, Jarrod W., Piotrowski, Mathew L., de Araujo, Elvin D., Sedighi, Abootaleb, Aghaei, Nikoo, Escudero, Laura, Ang, Patrick, Gwynne, William D., Zhang, Cunjie, Quaile, Andrew, McKenna, Dillon, Subapanditha, Minomi, Tokar, Tomas, Vaseem Shaikh, Muhammad, Zhai, Kui, Chafe, Shawn C., Gunning, Patrick T., Montenegro-Burke, J. Rafael, Venugopal, Chitra, Magolan, Jakob, Singh, Sheila K. |
| Zdroj: |
Cell Reports Medicine; October 2024, Vol. 5 Issue: 10 |
| Abstrakt: |
Patients with brain metastases (BM) face a 90% mortality rate within one year of diagnosis and the current standard of care is palliative. Targeting BM-initiating cells (BMICs) is a feasible strategy to treat BM, but druggable targets are limited. Here, we apply Connectivity Map analysis to lung-, breast-, and melanoma-pre-metastatic BMIC gene expression signatures and identify inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novoGTP synthesis pathway, as a target for BM. We show that pharmacological and genetic perturbation of IMPDH attenuates BMIC proliferation in vitroand the formation of BM in vivo.Metabolomic analyses and CRISPR knockout studies confirm that de novoGTP synthesis is a potent metabolic vulnerability in BM. Overall, our work employs a phenotype-guided therapeutic strategy to uncover IMPDH as a relevant target for attenuating BM outgrowth, which may provide an alternative treatment strategy for patients who are otherwise limited to palliation. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
